Views: 3510 Downloads: 557

Timur Saliev , Shynar Tanabayeva , Neilya Ussebayeva , Slu Izmailova , Bauyrzhan Umbayev , Gani Akhanov , Nurgulim Akhmad , Ildar Fakhradiyev^*✉

1. Department of Medicine, S.D.Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
2. Department of Medicine, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
3. Department of Medicine, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.

Abstract

Since the outbreak of the COVID-19 pandemic caused by the SARS-CoV-2 virus, there has been a pressing need for effective and accessible antiviral agents. Aminocaproic acid (Epsilon-aminocaproic acid, EACA), known primarily for its antifibrinolytic properties, has recently been in the spotlight for its potential cytotoxic and antiviral capabilities. This study aims to evaluate the in vitro cytotoxicity and antiviral activity of EACA against SARS-CoV-2.An in-depth in vitro analysis was conducted in isolated laboratories to determine the cytotoxic effects of EACA on cell cultures and its potential to inhibit SARS-CoV-2 replication. Assays to assess the direct in-vitro antiviral activity of EACA against the virus were performed (Vero E6 cell culture), considering viral entry inhibition and protein interaction disruption. The cytotoxic concentration (TTC50) for EACA on Vero E6 cell culture was set at 35,128 μg/ml (p ≤ 0.05). EACA at concentrations of 1093 μg/ml, 2187 μg/ml, 4375 μg/ml, 8750 μg/ml, 17500 μg/ml, 25000 μg/ml, and 35000 μg/ml does not have therapeutic or virus inhibitory activity against the SARS-CoV-2 virus at a dose of 100 TCD50/0.2 ml. The use of EACA for the treatment or prevention of SARS-CoV-2 may not be effective. This highlights the need to continue searching for other effective candidates from the protease inhibitors group‎.

Keywords: Aminocaproic acid, SARS-CoV-2, COVID-19, Cytotoxicity, Antiviral agents, Protease inhibitors

Citation Formats: